BeOne Medicines registers two Phase 1 hepatic impairment PK studies for sonrotoclax and tacabrutideg

BeOne Medicines registered two new Phase 1 pharmacokinetic studies in participants with hepatic impairment, both first posted October 2, 2026 and not yet recruiting.

• Sonrotoclax (BGB-11417, BEQALZI), a Bcl-2 inhibitor, is being tested in a single-dose study comparing participants with severe hepatic impairment to those with normal liver function. The study will enroll approximately 12 adults in the United States, 6 with serious liver problems and 6 with normal liver function.¹ Estimated start is October 15, 2026, with primary completion estimated February 8, 2027.
• Tacabrutideg (BGB-16673), a BTK degrader designed to attach to Bruton's tyrosine kinase, a protein that helps cancer cells survive, and tag it for removal², is being studied in participants with moderate and severe hepatic impairment versus normal liver function. The study will enroll approximately 24 adults in the United States, up to 16 with liver impairment and 8 with normal liver function.² Estimated start is October 22, 2026, with primary completion estimated July 31, 2027.